Withdrawn
Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma
2 January 2024
Condition
Blood and Immune System
Cancer
Published on 12 Jul 2022
Last Updated on 02 Jan 2024
Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma Guidance is outdated and has been withdrawn on 2 Jan 2024.
The Plain English Summary (PES) has been updated on 2 Jan 2024.
PES Treatments for mantle cell lymphoma (Updated 2 Jan 2024) [PDF, 150 KB] (opens in new tab)
